You are here: Industry Insights > Ionis

News List

Ionis Enters Collaboration with Partner to Develop IONIS-FB-LRx americanpharmaceuticalreview
October 12, 2018
Ionis announced a new collaboration with Roche to develop IONIS-FB-LRx for the treatment of complement-mediated diseases. This collaboration will leverage Ionis' leadership in RNA-targeted therapeutics to develop IONIS-FB-LRx targeting Factor B (FB) for a
US nod for Akcea/Ionis’ Tegsedi pharmatimes
October 11, 2018
Akcea and Ionis’ Tegsedi has won US approval for patients with hereditary transthyretin amyloidosis (hATTR), a rare disease causing build up of amyloid...
Biogen and Ionis Tie Up in $1 Billion Deal to Develop Neurological Therapies biospace
April 23, 2018
Shares of Ionis Pharmaceuticals are up more than 10 percent in premarket trading after Biogenhanded over $1 billion to support a new 10-year collaboration agreement to develop novel antisense drug candidates for a broad range of neurological diseases.
Ionis Licenses NASH Drug to AstraZeneca contractpharma
April 10, 2018
Ionis Pharmaceuticals, Inc. has licensed IONIS-AZ6-2.5-LRx, or AZD2693, to AstraZeneca following its advancement into development.
Ionis Pharmaceuticals Partners With Akcea Therapeutics in a Potential $1.7 Billion Deal biospace
March 16, 2018
In 2017, GlaxoSmithKline ended its partnership with Ionis Pharmaceuticals, Inc. to develop and market inotersen and a follow-up drug for rare diseases
Ionis and Roche Tout Positive Data in Early-Stage Huntington’s Disease Trial biospace
March 05, 2018
Three months ago Roche forked over a payment of $45 million for rights to Ionis Pharmaceuticals, Inc. investigational drug IONIS-HTTRx for the treatment of Huntington’s disease.
Ionis spinout Akcea files for approval of volanesorsen fiercebiotech
September 05, 2017
Akcea Therapeutics has filed for FDA approval of volanesorsen. The Ionis Pharmaceuticals spinout sees the filing positioning it to bring the treatment of familial chylomicronemia syndrome (FCS) to market in the U.S. next year.
Ionis Announces Phase 3 NEURO-TTR Study of Inotersen Meets Primary Endpoints americanpharmaceuticalreview
May 16, 2017
Ionis Pharmaceuticals announced the Phase 3 NEURO-TTR study of inotersen (IONIS-TTRRx) in patients with familial amyloid polyneuropathy (FAP) met both primary endpoints.
Ionis Earns $75M from Bayer for Advancing IONIS-FXI Rx and IONIS-FXI-L Rx americanpharmaceuticalreview
February 15, 2017
Ionis Pharmaceuticals has announced the advancement of IONIS-FXIRx in clinical development under an existing exclusive license agreement with Bayer.

Previous page 1 2 3 Next page